Stocks to watch: OCBC, FLCT, Keppel Infrastructure Trust, UltraGreen.ai

[SINGAPORE] The following companies saw new developments that may affect trading of their securities on Tuesday (May 5):

OCBC : The lender on Monday announced that it agreed to acquire the assets and liabilities of HSBC’s retail and wealth management operations in Indonesia, via its subsidiary Bank OCBC NISP Tbk. The move is expected to add S$6.6 billion to OCBC Indonesia’s assets under management, comprising S$4.3 billion of customers’ investments in mutual funds and bonds, and insurances and customer deposits of S$2.3 billion. A customer retail loan book of S$300 million will also be transferred to OCBC Indonesia. Shares of OCBC ended 0.1 per cent or S$0.03 down at S$21.87 ahead of the news.

Frasers Logistics & Commercial Trust (FLCT) : FLCT reported a 1.7 per cent drop in its distribution per unit (DPU) to S$0.0295 for its first half ended March 31, 2026, from S$0.03 the year before. Distributable income for the period declined 1 per cent year on year to S$111.9 million, from S$113 million. The decline in DPU was impacted by a lower capital distribution of S$6.6 million in H1 2026 compared with S$19.5 million in H1 2025. Units of FLCT closed S$0.01 or 1 per cent higher at S$0.97 on Tuesday before the results were released.

Keppel Infrastructure Trust (KIT) : KIT announced on Monday that it will acquire an additional 39 per cent stake in the Keppel Merlimau Cogen plant on Jurong Island for up to S$128.1 million. The transaction will increase KIT’s aggregate interest in the 1,300 megawatt facility to 90 per cent. Units of KIT closed flat at S$0.54 on Monday before the announcement.

UltraGreen.ai : The mainboard-listed group delivered 280,900 vial shipments for Q1 ended Mar 31, down by 8.7 per cent from 307,600 in the year-ago period. This came as Q1 2025 recorded inflows of back-order fulfilments from the prior quarter, contributing to strong volumes, said the group on Thursday. Separately, the fluorescence-guided surgery and digital health platform announced that it clinched regulatory approval for Verdye, an injectable form of indocyanine green dye, in Singapore, which supports commercialisation and clinical adoption. The counter ended Monday 2.1 per cent or US$0.03 higher at US$1.49, before the news.